Eris Lifesciences Limited, a leading Indian branded formulations company, has announced a breakthrough diabetes therapy with the launch of weekly shot of its generic semaglutide starting at Rs. 220 ...
Merck marks 10 years of SPARK mobilizing employee volunteers to help inspire the next generation in STEM: Our Bureau, Bengaluru Friday, March 20, 2026, 17:30 Hrs [IST] Merck, mark ...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes: Indianapolis Friday, March 20, ...
Waters Corporation announced that it has priced an offering of $3.5 billion aggregate principal amount of the following senior notes issued by its subsidiary, Augusta SpinCo Corporation. The offering ...
P&G SEHAT extends comprehensive health camps to 10,000 underserved women across 10 locations: Our Bureau, Bengaluru Friday, March 20, 2026, 16:45 Hrs [IST] P&G SEHAT, the healthca ...
Tata Elxsi launches a global offshore development centre for Terumo Corporation for cardiac and vascular solutions: Our Bureau, Bengaluru Friday, March 20, 2026, 12:15 Hrs [IST] T ...
Cenevo’s Labguru drives digital lab transformation for Pace Life Sciences: London Friday, March 20, 2026, 18:00 Hrs [IST] Cenevo, a company specializes in lab management systems ...
Illumina and Labcorp expand collaboration to advance precision oncology through innovative applications of NGS solutions: San Diego Friday, March 20, 2026, 15:00 Hrs [IST] Illumin ...
Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...
MiniMed receives US FDA clearance of MiniMed Flex, the company's smallest insulin pump featuring its first smartphone-controlled design: Northridge, California Friday, March 20, 2 ...
Chugai Pharma files regulatory application with Japanese MHLW for medical device component of the Port Delivery Platform with ranibizumab: Tokyo Friday, March 20, 2026, 11:00 Hrs ...
Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...